Under construction – not a live service
Sign in

2026-527268-33-00Not yet recruitingPhase 1

PANVIRAL: Safety, Feasibility and Immunogenicity of Intra-Tumoral ORCA-010 Oncolytic Virus Administration in Metastatic Pancreatic Cancer – A Single-Center Phase 1 Trial

Source: EU CTIS (euclinicaltrials.eu) · Last updated 9 Oct 2026

Next steps

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
15 (estimated)
First submitted
22 Jun 2026
Start date
1 Jan 2027
Lead sponsor
Amsterdam UMC Stichting
EU CT number
2026-527268-33-00

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 15
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with metastatic pancreatic cancer to test the safety and immune response of ORCA-010, an oncolytic virus injected into the tumor.

Age
18 years or older
Sex
All sexes can join
Disease stage
Metastatic pancreatic cancer

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Amsterdam UMC StichtingAmsterdamNetherlandsNot yet recruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.